A Phase 1 interventional study of HMPL-653 in Advanced Malignant Solid Tumors and TGCT, sponsored by Hutchison Medipharma Limited. Status unknown at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-14.
Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.
Hutchison Medipharma Limited is the lead sponsor of 68 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dose-escalation Stage: Participants will be treated with escalating doses of HMPL-653 to determine the MTD and RP2D. Dose-expansion Stage: Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of HMPL-653 in TGCT and specific advanced solid tumors.
Drug: HMPL-653
Dose-escalation Stage: Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment. Dose-expansion Stage: The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment.
Occurrence of Dose-Limiting Toxicities(DLTs)
To evaluate the safety and tolerability of HMPL-653 for dose escalation period
Time frame: up to 33 days
Maximum tolerated dose (MTD)
The Maximum tolerated dose of HMPL-653
Time frame: up to 12 months
Recommended phase II dose (RP2D)
Recommended phase II dose of HMPL-653
Time frame: up to 12 months
Pharmacokinetic-Cmax
Peak concentration of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-Tmax
Time to peak concentration of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-Ctrough
Trough concentration of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-t1/2
Terminal elimination half-life of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-AUC0-t
Area under the plasma concentration-time curve of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-AUC0-∞
Area under the plasma concentration-time curve of Pharmacokinetic
Time frame: From first dose up to C3D1, estimated up to 9 weeks
Pharmacokinetic-AUC0-τ
Area under the plasma concentration-time curve of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-CL/F
Apparent clearance of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-Vz/F
Apparent volume of distribution in the terminal phase of Pharmacokinetic
Time frame: up to 9 weeks
Pharmacokinetic-AR
AUC-based accumulation coefficient of Pharmacokinetic
Time frame: up to 9 weeks
Objective response rate (ORR)
The incidence of confirmed complete response or partial response.
Time frame: 12 months
Progression-free survival (PFS)
The time from the first dose of study treatment to PD or death for any reason, whichever comes first.
Time frame: 12 months
Disease control rate (DCR)
The proportion of patients with confirmed CR or PR or stable disease (SD) as the best response, and the duration of SD needs to be ≥6 weeks.
Time frame: 12 months
Time to response (TTR)
The time from the first dose of HMPL-653 to the first objective response.
Time frame: 12 months
Duration of response (DoR)
The time from the first appearance of confirmed CR or PR to PD or death for any reason (whichever comes first), in the patients with objective response.
Time frame: 12 months
Overall survival (OS)
The time from the first dose of study treatment to death for any reason.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2022 (actual). Primary completion is estimated for Jun 2024, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hutchison Medipharma Limited →